Sitagliptin: uses, dosing, side effects & brands

Brynovin (Sitagliptin Hydrochloride) is a dipeptidyl peptidase 4 inhibitor used to treat Type 2 Diabetes Mellitus.

The FDA classifies sitagliptin as a dipeptidyl peptidase 4 inhibitor. DPP-4 inhibitors block the enzyme that quickly destroys the body's own gut hormones (incretins like GLP-1). With these hormones lasting longer, the pancreas releases more insulin and less glucagon after meals, which lowers blood sugar. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.

The elimination half-life of sitagliptin is about 12.4 hours (apparent terminal half-life after a single 100 mg oral dose in healthy volunteers) — that is how long the body takes to clear half of a dose. This is the apparent terminal (elimination) half-life the label reports; it does not describe a separate distribution phase. Sitagliptin is not a prodrug and has no active metabolite that outlasts it — metabolism is a minor pathway (about 16% of the dose), and the label states that the six metabolites detected were at trace levels and are not expected to contribute to DPP-4 inhibition. About 79% of the drug is excreted unchanged in the urine, so the kidneys drive elimination: the label reports an approximately 2-fold higher sitagliptin AUC in moderate renal impairment (eGFR 30 to under 45 mL/min/1.73 m2) and an approximately 4-fold higher AUC in severe impairment and end-stage renal disease on hemodialysis, versus healthy controls — the label quantifies these as exposure (AUC) increases rather than restating a longer half-life. Older adults (65 to 80 years) had about 19% higher plasma concentrations than younger subjects, and the label says that once the effect of age on renal function is accounted for, age alone has no clinically meaningful impact on sitagliptin pharmacokinetics. Moderate hepatic impairment (Child-Pugh 7 to 9) raised AUC by only about 21% and Cmax by about 13%, which the label calls not clinically meaningful; there is no clinical experience in severe hepatic impairment (Child-Pugh over 9). Half-life is not the same as how long a drug test can detect the drug, and it varies with age, kidney and liver function.

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run sitagliptin against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

We track 5 sitagliptin-containing products in the U.S.: Brynovin, Sitagliptin Phosphate, Januvia, Sitagliptin and Zituvio. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.

Across the brands we track, sitagliptin is currently marketed as solution and tablet, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Yes. Our catalog lists 2 generic sitagliptin products alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.

Cold-type symptoms and headache. These answers are for Januvia tablets, the sitagliptin product most people search for. Reactions reported in at least 5% of patients were upper respiratory tract infection, nasopharyngitis (stuffy or runny nose and sore throat) and headache. Sitagliptin alone is not a big hypoglycemia driver, but the label notes that when it is added to insulin or a sulfonylurea, a lower dose of the insulin or sulfonylurea may be needed to keep blood sugar from dropping too low.

No. Januvia has no boxed warning. Its serious risks appear in Warnings and Precautions instead: acute pancreatitis, including reported fatal hemorrhagic or necrotizing cases; acute kidney failure; a heart failure signal seen in cardiovascular outcome trials of two other drugs in the same DPP-4 inhibitor class; serious allergic reactions including anaphylaxis, angioedema and skin conditions such as Stevens-Johnson syndrome; bullous pemphigoid; and severe, disabling joint pain. Absence of a box does not mean absence of risk — it means these warnings are printed in the body of the label.

Anyone who has had a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema. That is the only contraindication on the label. Beyond that, it is a dose question rather than a ban: the label reduces the dose by kidney function, keeping the standard dose at an eGFR of 45 or above, dropping to 50 mg once daily at an eGFR of 30 to 44, and 25 mg once daily below 30. The label also recommends checking kidney function before you start and periodically afterward.

Severe, persistent stomach pain, sometimes radiating to your back and sometimes with vomiting — that is the pancreatitis pattern the label tells prescribers to watch for after starting Januvia, and the drug should be stopped promptly if pancreatitis is suspected. Also call about new blisters or skin erosions, which can signal bullous pemphigoid; severe joint pain, which can be disabling and improves when the drug is stopped; and swelling of the face, lips or throat, trouble breathing, or peeling rash, which point to serious hypersensitivity.

The label flags it as a possible class risk rather than a proven sitagliptin effect. It states that an association between DPP-4 inhibitor treatment and heart failure was observed in cardiovascular outcomes trials for two other members of the class, and it tells prescribers to consider the risks and benefits before starting Januvia in patients already at risk for heart failure. If you have heart failure or reduced ejection fraction, raise it before starting, and report new shortness of breath, unusual fatigue, or rapid weight gain from fluid.